Neurotez
Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.
Overview
Raised: $95,809
2005
Healthcare & Pharmaceuticals
Biotech
Bridgewater, New Jersey
Are you, or is someone in your life, impacted by Alzheimer’s? Is so, Neurotez Inc. could be the investment you’ve been looking for. Their highly experienced team is developing a drug to treat Leptin deficiency in Alzheimer’s patients and/or act as a preventative for those who are at risk, and their drug might just be the missing piece needed to help fight this terrible disease.
The Company:
Neurotez Inc. is on a mission to become the world leaders in biotechnology and to help Alzheimer’s patients with drugs that are both safe and efficacious. Their primary goal is to develop a Leptin product as an innovative hormone replacement therapy for Alzheimer’s disease and/or as a preventative for those who are at risk. Today’s medications provide limited relief, and current efforts, which focus on removing either Abeta or tau deposits from the brain, have not generated any effective drugs for the last 18 years. Neurotez is here to change that -- by focusing on Leptin instead and attacking the disease in a new way. So far, Neurotez has been nominated as the Most Promising Private Company in 2015 by the Biotechnology Industry Organization, as well as a 2010 Incubator Company to Watch at the NJTC Gala Awards. Add in that their team has deep experience and success with thousands of publications in Alzheimer’s, and you can see why Neurotez might just be the Alzheimer's weapon we’ve been waiting for.
The Bottom Line:
Neurotez Inc. is changing the game when it comes to treating and fighting Alzheimer’s. Their Leptin product attacks the disease in a new way, and with Alzheimer’s affecting more than five million Americans and 18 million patients worldwide, we need all the help we can get. This innovative treatment might be just what patients need to help with -- or prevent -- the devastating effects of Alzheimer’s.
Raise History
Offering Name | Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|---|
Neurotez | 01/27/2023 | Netcapital | $45,272,228 | $15,952 | Equity - Common | Funded | RegCF |
Neurotez | 03/10/2022 | StartEngine | $44,870,036 | $33,845 | Equity - Common | Funded | RegCF |
Neurotez | 06/24/2021 | Netcapital | $21,959,058 | $255,718 | Equity - Common | Funded | RegCF |
Neurotez | 02/26/2018 | Netcapital | $24,544,690 | $95,809 | Equity - Common | Funded | RegCF |
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Employee History
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual